Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 mars 2018 07h00 HE | Source: BeiGene, LTD.

BeiGene to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. and BEIJING, China, March 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
28 févr. 2018 16h05 HE | Source: BeiGene, LTD.

BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results

CAMBRIDGE, Mass. and BEIJING, China, Feb. 28, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
27 févr. 2018 18h00 HE | Source: BeiGene, LTD.

BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China

BEIJING, China, and CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
09 févr. 2018 14h45 HE | Source: BeiGene, LTD.

BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium

CAMBRIDGE, Mass., and BEIJING, China, Feb. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
07 févr. 2018 06h00 HE | Source: BeiGene, LTD.

BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference

CAMBRIDGE, Mass. and BEIJING, China, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
05 févr. 2018 18h00 HE | Source: BeiGene, LTD.

BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China

BEIJING, China, and CAMBRIDGE, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
05 févr. 2018 17h30 HE | Source: BeiGene, LTD.

BeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers Symposium

CAMBRIDGE, Mass. and BEIJING, China, Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
31 janv. 2018 06h00 HE | Source: BeiGene, LTD.

BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma

CAMBRIDGE, Mass. and BEIJING, China, Jan. 31, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
22 janv. 2018 16h05 HE | Source: BeiGene, LTD.

BeiGene Announces Closing of $800 Million Public Offering

CAMBRIDGE, Mass. and BEIJING, China, Jan. 22, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
17 janv. 2018 23h21 HE | Source: BeiGene, LTD.

BeiGene Announces Pricing of $750 Million Public Offering

CAMBRIDGE, Mass. and BEIJING, China, Jan. 17, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...

Page précédente